Focused on

Finding a

Cure

The Syncromune Team is dedicated to developing combination multi-target immunotherapies to fight metastatic solid tumors in a new way

Focused on

Finding a

Cure

The Syncromune Team is dedicated to developing combination multi-target immunotherapies to fight metastatic solid tumors in a new way

Pioneers in Combination Multi-Target Immunotherapy

Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized in situ therapy that combines partial tumor oncolysis and a multi-target biologic drug.  The SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in Phase 1 trials.

Our Mission

We aspire to develop a completely in situ immunotherapy platform technology optimized for solid tumor cancers that achieves high response rates with potentially curative efficacy

Our Values

C

Caring

Every member of the Syncromune team is inspired by the opportunities to change the lives of patients and their families and bring hope to those who have exhausted their treatment options.

U

Unique

At Syncromune we are doing things that have never been done and developing a disruptive technology that is paving the way for a whole new approach to treating metastatic solid tumor cancers.

R

Relentless

We are focused every day on our pursuit of developing a cure for metastatic solid tumor cancers.  Our team works relentlessly with the goal of helping patients in need. 

E

Ethical

Syncromune is committed to maintaining high standards of personal conduct, practicing honesty in all our professional relationships and endeavors. We believe in being truthful in our actions and words.

Executive Leadership

CHARLES LINK, MD

EXECUTIVE CHAIRMAN

EAMONN HOBBS

PRESIDENT & CEO

JEFFREY KRAWS

CHIEF FINANCIAL OFFICER

JONATHAN LEWIS, MD, PHD

CHIEF MEDICAL OFFICER

GREGORY CHAMPION

CHIEF LEGAL OFFICER

AGUSTIN GAGO

CHIEF OPERATING OFFICER

MARIO MAUTINO, PHD

CHIEF SCIENTIFIC OFFICER

Board of Directors

CHARLES LINK, MD

EXECUTIVE CHAIRMAN

EAMONN HOBBS

PRESIDENT & CEO

DOUGLAS WATSON

LEAD INDEPENDENT DIRECTOR

JEFFREY CLELAND, PHD

INDEPENDENT DIRECTOR

JOSEPH MAROON, MD

INDEPENDENT DIRECTOR

NORMAN SCHWARTZ

INDEPENDENT DIRECTOR

Scientific Advisory Board

JAMES ARMITAGE, M.D.

  • The Joe Shapiro Professor of Medicine Professor, Division of Oncology & Hematology, UNMC
  • Past President of ASTCT and ASCO

GEORGE C. PRENDERGAST, PH.D.

  • President and CEO of the Lankenau Institute for Medical Research (LIMR)
  • Former Editor-in-Chief of Cancer Research

RICHARD HARRIS, M.D.

  • CEO of UroPartners
  • Past President of Large Urology Group Practice Association (LUGPA) BOD

THOMAS RAFFIN, M.D.

  • Stanford University School of Medicine Colleen and Robert Haas Professor Emeritus of Medicine and Biomedical Ethics
  • Former Chief of Pulmonary and Critical Care Medicine

ALAN EPSTEIN, PH.D.

  • University of Southern California
  • Professor, Keck School of Medicine

DAVID VAUGHAN, M.D.

  • Former Chairman of Department of Urology at Florida Hospital & Winter Park Hospital
  • Former Partner of Orlando Urology Associates

SUMING WANG, M.D., PH.D.

  • Founded Shanghai Mingda Biotech, an immune therapy company in 2014
  • Former CEO of Shanghai East International Medical Center
  • Vice President of NewLink Genetics from 1999-2008

YOUSEF ZAKHARIA, M.D.

  • Clinical Associate Professor of Medicine, University of Iowa
  • Director Phase I Program, Co-Leader Genitourinary Oncology Program, University of Iowa

Disclaimers: The content on this website is intended for healthcare professionals. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the relevant regulatory authorities, including the US Food and Drug Administration or other applicable agencies in other countries.

2919 E. Commercial Blvd.
Fort Lauderdale, FL 33308